BioCentury | Feb 15, 2016
Politics, Policy & Law

Nature won't wait

...vaccine that is in a Phase II trial, as part of its 2013 acquisition of Inviragen Inc....
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...vaccines business, including the 2012 acquisition of LigoCyte Pharmaceuticals Inc. and the 2013 acquisition of Inviragen Inc....
...product, a norovirus VLP intranasal vaccine, is in Phase II testing to prevent norovirus gastroenteritis. Inviragen's...
BioCentury | Sep 23, 2013
Finance

School supplies

...total of $118 million and produced ophthalmic surgery company LenSx Lasers Inc. and vaccine play Inviragen Inc....
...Pharmaceutical Co. Ltd. (Tokyo:4502) paid $35 million plus up to $215 million in milestones for Inviragen...
BioCentury | May 13, 2013
Company News

Inviragen, Takeda deal

...Inviragen for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's...
...Takeda, which also will gain Inviragen's vaccine development center in Singapore, said it will integrate Inviragen...
...LLC was Inviragen's financial advisor, and Wilson Sonsini Goodrich & Rosati was Inviragen's legal advisor. Inviragen Inc....
BioCentury | May 9, 2013
Company News

Takeda acquiring Inviragen

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will acquire infectious disease company Inviragen Inc. (Fort Collins. Colo.) for $35...
...Colo.) for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's...
...Takeda, which also will gain Inviragen's vaccine development center in Singapore, said it will integrate Inviragen...
BioCentury | Mar 4, 2013
Clinical News

DENVax: Phase II ongoing

...18 months to 11 years old. Data from the first stage are expected this year. Inviragen Inc....
BioCentury | Jan 14, 2013
Company News

Inviragen, The Company for Vaccine and Biological Production No. 1 deal

...Cambodia and Myanmar a Japanese encephalitis (JE) vaccine based on Inviragen's cell-based JE production technology. Inviragen...
...vaccines and biologics. Inviragen declined to disclose additional details, while VABIOTECH could not be reached. Inviragen Inc....
BioCentury | Mar 19, 2012
Clinical News

Enterovirus 71 vaccine: Phase I data

...weeks apart induced neutralizing EV71 antibody responses in all subjects. The vaccine was well tolerated. Inviragen...
...it plans to evaluate the safety and efficacy of INV21 in children later this year. Inviragen Inc....
BioCentury | Jan 9, 2012
Clinical News

DENVax: Phase I data

...Hygiene meeting in Philadelphia. Last November, Inviragen started a Phase II trial of the vaccine. Inviragen Inc....
BioCentury | Dec 5, 2011
Clinical News

DENVax: Phase II started

...to evaluate 2 doses of DENVax given 3 months apart in subject ages >=18 months. Inviragen Inc....
Items per page:
1 - 10 of 27
BioCentury | Feb 15, 2016
Politics, Policy & Law

Nature won't wait

...vaccine that is in a Phase II trial, as part of its 2013 acquisition of Inviragen Inc....
BioCentury | Oct 13, 2014
Strategy

Streamlining Takeda's Profit Story

...vaccines business, including the 2012 acquisition of LigoCyte Pharmaceuticals Inc. and the 2013 acquisition of Inviragen Inc....
...product, a norovirus VLP intranasal vaccine, is in Phase II testing to prevent norovirus gastroenteritis. Inviragen's...
BioCentury | Sep 23, 2013
Finance

School supplies

...total of $118 million and produced ophthalmic surgery company LenSx Lasers Inc. and vaccine play Inviragen Inc....
...Pharmaceutical Co. Ltd. (Tokyo:4502) paid $35 million plus up to $215 million in milestones for Inviragen...
BioCentury | May 13, 2013
Company News

Inviragen, Takeda deal

...Inviragen for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's...
...Takeda, which also will gain Inviragen's vaccine development center in Singapore, said it will integrate Inviragen...
...LLC was Inviragen's financial advisor, and Wilson Sonsini Goodrich & Rosati was Inviragen's legal advisor. Inviragen Inc....
BioCentury | May 9, 2013
Company News

Takeda acquiring Inviragen

...Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) will acquire infectious disease company Inviragen Inc. (Fort Collins. Colo.) for $35...
...Colo.) for $35 million in cash up front, plus up to $215 million in milestones. Inviragen's...
...Takeda, which also will gain Inviragen's vaccine development center in Singapore, said it will integrate Inviragen...
BioCentury | Mar 4, 2013
Clinical News

DENVax: Phase II ongoing

...18 months to 11 years old. Data from the first stage are expected this year. Inviragen Inc....
BioCentury | Jan 14, 2013
Company News

Inviragen, The Company for Vaccine and Biological Production No. 1 deal

...Cambodia and Myanmar a Japanese encephalitis (JE) vaccine based on Inviragen's cell-based JE production technology. Inviragen...
...vaccines and biologics. Inviragen declined to disclose additional details, while VABIOTECH could not be reached. Inviragen Inc....
BioCentury | Mar 19, 2012
Clinical News

Enterovirus 71 vaccine: Phase I data

...weeks apart induced neutralizing EV71 antibody responses in all subjects. The vaccine was well tolerated. Inviragen...
...it plans to evaluate the safety and efficacy of INV21 in children later this year. Inviragen Inc....
BioCentury | Jan 9, 2012
Clinical News

DENVax: Phase I data

...Hygiene meeting in Philadelphia. Last November, Inviragen started a Phase II trial of the vaccine. Inviragen Inc....
BioCentury | Dec 5, 2011
Clinical News

DENVax: Phase II started

...to evaluate 2 doses of DENVax given 3 months apart in subject ages >=18 months. Inviragen Inc....
Items per page:
1 - 10 of 27